{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:24:47Z","timestamp":1787509487078,"version":"build-2736575974"},"reference-count":36,"publisher":"Begell House","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Crit Rev Eukaryot Gene Expr"],"published-print":{"date-parts":[[2025]]},"abstract":"<p>Methyltransferase-like 14 (METTL14) has been identified as a protective factor in central nervous system disorders, yet its involvement in Parkinson's disease (PD) remains underexplored. This study aimed to investigate the role of METTL14 in PD. An &lt;i&gt;in vitro&lt;\/i&gt; PD model was established by exposing neurons to 1-methyl-4-phenylpyridinium (MPP&lt;sup&gt;&amp;#43;&lt;\/sup&gt;). mRNA levels were quantified via real-time-quantitative PCR. Protein expression was assessed through Western blot. The release of pyroptosis-related cytokines was detected using enzyme-linked immunosorbent assay. N6-methyladenosine (m6A) levels were measured using an m6A assay. m6A enrichment was pinpointed with a methylated RNA immunoprecipitation assay. The transcriptional activity of nuclear factor, erythroid 2 (NFE2) was evaluated using a luciferase assay. Cell viability, neuronal cytotoxicity, and neuronal death were respectively determined using Cell Counting Kit-8, lactate dehydrogenase, and terminal deoxynucleotidyl transferase dUTP nick-end labeling assays. Our findings unveiled that METTL14 expression is diminished following MPP+ exposure, which in turn triggers neuroinflammation and pyroptosis. Conversely, overexpression of METTL14 mitigates neuroinflammation and pyroptosis, and restores neuronal function. Mechanistically, METTL14 augments the m6A modification of NFE2 at a specific site, thereby preserving its mRNA stability. However, NFE2 knockdown exacerbates neuroinflammation and pyroptosis. In summary, METTL14 safeguards against neurodegeneration in PD by modulating the m6A modification of NFE2, positioning the METTL14\/NFE2 axis as a potential therapeutic target for PD.<\/p>","DOI":"10.1615\/critreveukaryotgeneexpr.2025059356","type":"journal-article","created":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T14:13:02Z","timestamp":1749564782000},"page":"47-57","source":"Crossref","is-referenced-by-count":2,"title":["METTL14 Inhibits the Pyroptosis of Neurons in Parkinson's Disease via Upregulating NFE2"],"prefix":"10.1615","volume":"35","author":[{"given":"Xiaoli","family":"Hou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huishen","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"613","reference":[{"key":"2","doi-asserted-by":"crossref","unstructured":"Tolosa E, Garrido A, Scholz SW, Poewe W. Challenges in the diagnosis of Parkinson's disease. Lancet Neurol. 2021;20(5):385-97.","DOI":"10.1016\/S1474-4422(21)00030-2"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Vijiaratnam N, Simuni T, Bandmann O, Morris HR, Foltynie T. Progress towards therapies for disease modification in Parkinson's disease. Lancet Neurol. 2021;20(7):559-72.","DOI":"10.1016\/S1474-4422(21)00061-2"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Ben-Shlomo Y, Darweesh S, Llibre-Guerra J, Marras C, San Luciano M, Tanner C. The epidemiology of Parkinson's disease. Lancet. 2024;403(10423):283-92.","DOI":"10.1016\/S0140-6736(23)01419-8"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Gao C, Liu J, Tan Y, Chen S. Freezing of gait in Parkinson\u00e2\u0080\u0099s disease: Pathophysiology, risk factors and treatments. Transl Neurodegener. 2020;9:12.","DOI":"10.1186\/s40035-020-00191-5"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Grotewold N, Albin RL. Update: Protective and risk factors for Parkinson disease. Parkinsonism Relat Disord. 2024;125:107026.","DOI":"10.1016\/j.parkreldis.2024.107026"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Ara\u00fajo B, Caridade-Silva R, Soares-Guedes C, Martins-Macedo J, Gomes ED, Monteiro S, Teixeira FG. Neuroinflammation and Parkinson's disease-from neurodegeneration to therapeutic opportunities. Cells. 2022;11(18):2908.","DOI":"10.3390\/cells11182908"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Claudino Dos Santos JC, Lima MPP, Brito GAC, Viana GSB. Role of enteric glia and microbiota-gut-brain axis in Parkinson disease pathogenesis. Ageing Res Rev. 2023;84:101812.","DOI":"10.1016\/j.arr.2022.101812"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Rao Z, Zhu Y, Yang P, Chen Z, Xia Y, Qiao C, Liu W, Deng H, Li J, Ning P, Wang Z. Pyroptosis in inflammatory diseases and cancer. Theranostics. 2022;12(9):4310.","DOI":"10.7150\/thno.71086"},{"key":"10","doi-asserted-by":"crossref","unstructured":"He X, Yang W, Zeng Z, Wei Y, Gao J, Zhang B, Li L, Liu L, Wan Y, Zeng Q, Gong Z. NLRP3-dependent pyroptosis is required for HIV-1 gp120-induced neuropathology. Cell Mol Immunol. 2020;17(3):283-99.","DOI":"10.1038\/s41423-019-0260-y"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Han YH, Liu XD, Jin MH, Sun HN, Kwon T. Role of NLRP3 inflammasome-mediated neuronal pyroptosis and neuroinflammation in neurodegenerative diseases. Inflamm Res. 2023;72(9):1839-59.","DOI":"10.1007\/s00011-023-01790-4"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Poli G, Fabi C, Sugoni C, Bellet MM, Costantini C, Luca G, Brancorsini S. The role of NLRP3 inflammasome activation and oxidative stress in varicocele-mediated male hypofertility. Int J Mol Sci. 2022;23(9):5233.","DOI":"10.3390\/ijms23095233"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Su B, Ren Y, Yao W, Su Y, He Q. Mitochondrial dysfunction and NLRP3 inflammasome: Key players in kidney stone formation. BJU Int. 2024;134(5):696-713.","DOI":"10.1111\/bju.16454"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Xian H, Watari K, Sanchez-Lopez E, Offenberger J, Onyuru J, Sampath H, Ying W, Hoffman HM, Shadel GS, Karin M. Oxidized DNA fragments exit mitochondria via mPTP-and VDAC-dependent channels to activate NLRP3 inflammasome and interferon signaling. Immunity. 2022;55(8):1370-85.","DOI":"10.1016\/j.immuni.2022.06.007"},{"key":"15","doi-asserted-by":"crossref","unstructured":"Li Y, Xia Y, Yin S, Wan F, Hu J, Kou L, Sun Y, Wu J, Zhou Q, Huang J, Xiong N. Targeting microglial \u00ce\u00b1-synuclein\/TLRs\/NF-kappaB\/NLRP3 inflammasome axis in Parkinson's disease. Front Immunol. 2021;12:719807.","DOI":"10.3389\/fimmu.2021.719807"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Li Y, Jin H, Li Q, Shi L, Mao Y, Zhao L. The role of RNA methylation in tumor immunity and its potential in immunotherapy. Mol Cancer. 2024;23(1):130.","DOI":"10.1186\/s12943-024-02041-8"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Guo S, Chen F, Li L, Dou S, Li Q, Huang Y, Li Z, Liu W, Zhang G. Intracellular Fusobacterium nucleatum infection increases METTL3-mediated m6A methylation to promote the metastasis of esophageal squamous cell carcinoma. J Adv Res. 2024;61:165-78.","DOI":"10.1016\/j.jare.2023.08.014"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Wang YF, Zhang WL, Li ZX, Liu Y, Tan J, Yin HZ, Zhang ZC, Piao XJ, Ruan MH, Dai ZH, Wang SJ. METTL14 downregulation drives S100A4+ monocyte-derived macrophages via MyD88\/NF-kB pathway to promote MAFLD progression. Signal Transduct Target Ther. 2024;9(1):91.","DOI":"10.1038\/s41392-024-01797-1"},{"key":"19","doi-asserted-by":"crossref","unstructured":"Kim SJ, Hyun J. Unraveling the role of METTL14 in metabolic dysfunction-associated fatty liver disease: Insights and therapeutic implications. Signal Transduct Target Ther. 2024;9(1):115.","DOI":"10.1038\/s41392-024-01837-w"},{"key":"20","doi-asserted-by":"crossref","unstructured":"Wang J, Fan P, Shen P, Fan C, Zhao P, Dong K, Ling R, Chen S, Zhang J. XBP1s activates METTL3\/METTL14 for ER-phagy and paclitaxel sensitivity regulation in breast cancer. Cancer Lett. 2024;596:216846.","DOI":"10.1016\/j.canlet.2024.216846"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Li J, Wei L, Hu K, He Y, Gong G, Liu Q, Zhang Y, Zhou K, Guo J, Hua Y, Tang J. Deciphering m6A methylation in monocyte-mediated cardiac fibrosis and monocyte-hitchhiked erythrocyte microvesicle biohybrid therapy. Theranostics. 2024;14(9):3486.","DOI":"10.7150\/thno.95664"},{"key":"22","doi-asserted-by":"crossref","unstructured":"Zhang X, Du P, Bai B, Lian X, Xue G. Molecular mechanism of METTL14-mediated m6A modification regulating microglial function post ischemic stroke. Brain Res Bull. 2025;220:111156.","DOI":"10.1016\/j.brainresbull.2024.111156"},{"key":"23","doi-asserted-by":"crossref","unstructured":"Shao L, Hu F, Xu R, Nie H, Zhang H, Zhang P. METTL14 regulates the m6A modification of TRAF6 to suppress mitochondrial dysfunction and ferroptosis in dopaminergic neurons via the cGAS-STING pathway. Curr Mol Med. 2024;24(12):1518-28.","DOI":"10.2174\/0115665240263859231018110107"},{"key":"24","doi-asserted-by":"crossref","unstructured":"Zhou Y, \u00c4\u0086orovi\u00c4\u0087 M, Hoch-Kraft P, Meiser N, Mesitov M, K\u00f6rtel N, Back H, Naarmann-de Vries IS, Katti K, Obrdl\u00edk A, Busch A. m6A sites in the coding region trigger translation-dependent mRNA decay. Mol Cell. 2024;84(23):4576-93.","DOI":"10.1016\/j.molcel.2024.10.033"},{"key":"25","doi-asserted-by":"crossref","unstructured":"Zhong X, Chen L, Wang Y, Liang Y, Huang Y, Chen Z, Cao W, Liu J, Zu X. METTL14\/YTHDC1-mediated m6A modification in hippocampus improves pentylenetetrazol-induced acute seizures. Mol Neurobiol. 2024:1-3.","DOI":"10.21203\/rs.3.rs-3743108\/v1"},{"key":"26","doi-asserted-by":"crossref","unstructured":"Gu X, Song Y, Liu X, Cheng Z, Min J, Zhang Y. METTL14-Mediated m6A modification of TUG1 represses ferroptosis in Alzheimer's disease via inhibiting GDF15 ubiquitination. Front Biosci. 2024;29(8):298.","DOI":"10.31083\/j.fbl2908298"},{"key":"27","doi-asserted-by":"crossref","unstructured":"Lu W, Yang X, Zhong W, Chen G, Guo X, Ye Q, Xu Y, Qi Z, Ye Y, Zhang J, Wang Y. METTL14-mediated m6A epitranscriptomic modification contributes to chemotherapy-induced neuropathic pain by stabilizing GluN2A expression via IGF2BP2. J Clin Invest. 2024;134(6).","DOI":"10.1172\/JCI174847"},{"key":"28","doi-asserted-by":"crossref","unstructured":"Gao G, Duan Y, Chang F, Zhang T, Huang X, Yu C. METTL14 promotes apoptosis of spinal cord neurons by inducing EEF1A2 m6A methylation in spinal cord injury. Cell Death Discov. 2022;8(1):15.","DOI":"10.1038\/s41420-021-00808-2"},{"key":"29","doi-asserted-by":"crossref","unstructured":"He H, Zhang Q, Liao J, Lei J, Luo M, Huang J, Chen M, Shen Y, Wang J, Xu P, Xiao Y. METTL14 is decreased and regulates m6A modification of \u00ce\u00b1-synuclein in Parkinson's disease. J Neurochem. 2023 Aug;166(3):609-22.","DOI":"10.1111\/jnc.15882"},{"key":"30","doi-asserted-by":"crossref","unstructured":"Qin L, Min S, Shu L, Pan H, Zhong J, Guo J, Sun Q, Yan X, Chen C, Tang B, Xu Q. Genetic analysis of N6-methyladenosine modification genes in Parkinson's disease. Neurobiol Aging. 2020;93:143-e9.","DOI":"10.1016\/j.neurobiolaging.2020.03.018"},{"key":"31","doi-asserted-by":"crossref","unstructured":"Teng Y, Liu Z, Chen X, Liu Y, Geng F, Le W, Jiang H, Yang L. Conditional deficiency of m6A methyltransferase Mettl14 in substantia nigra alters dopaminergic neuron function. J Cell Mol Med. 2021;25(17):8567-72.","DOI":"10.1111\/jcmm.16740"},{"key":"32","doi-asserted-by":"crossref","unstructured":"Liu TC, Li HX, Wan YX, Shi G, Zhao YP, Liu YF, Fan XY. METTL14-mediated upregulation of lncRNA HOTAIR represses PP1a expression by promoting H3K4me1 demethylation in oxycodone-treated mice. CNS Neurosci Ther. 2024;30(7):e14830.","DOI":"10.1111\/cns.14830"},{"key":"33","doi-asserted-by":"crossref","unstructured":"Wu L, Luo Z, Luo F, Huang T, Cen Y, Rao G, Zhao Z, Ou R, Zhou M. Edaravone inhibits neuronal ferroptosis and alleviates acute central nervous system injury induced by diquat via enhancement of METTL14-mediated m6A methylation of Aldh1l1. Free Radic Res. 2025;59(3):274-88.","DOI":"10.1080\/10715762.2025.2482774"},{"key":"34","doi-asserted-by":"crossref","unstructured":"Boas SM, Joyce KL, Cowell RM. The NRF2-dependent transcriptional regulation of antioxidant defense pathways: Relevance for cell type-specific vulnerability to neurodegeneration and therapeutic intervention. Antioxidants. 2021;11(1).","DOI":"10.3390\/antiox11010008"},{"key":"35","doi-asserted-by":"crossref","unstructured":"Wei Y, Lu M, Mei M, Wang H, Han Z, Chen M, Yao H, Song N, Ding X, Ding J, Xiao M. Pyridoxine induces glutathione synthesis via PKM2-mediated Nrf2 transactivation and confers neuroprotection. Nat Commun. 2020;11(1):941.","DOI":"10.1038\/s41467-020-14788-x"},{"key":"36","doi-asserted-by":"crossref","unstructured":"Zhang C, Zhao M, Wang B, Su Z, Guo B, Qin L, Zhang W, Zheng R. The Nrf2-NLRP3-caspase-1 axis mediates the neuroprotective effects of Celastrol in Parkinson's disease. Redox Biol. 2021;47:102134.","DOI":"10.1016\/j.redox.2021.102134"},{"key":"37","doi-asserted-by":"crossref","unstructured":"Peng S, Chen Y, Wang R, Zhang J. Z-ligustilide provides a neuroprotective effect by regulating the phenotypic polarization of microglia via activating Nrf2-TrxR axis in the Parkinson's disease mouse model. Redox Biol. 2024;76:103324.","DOI":"10.1016\/j.redox.2024.103324"}],"container-title":["Critical Reviews in Eukaryotic Gene Expression"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dl.begellhouse.com\/download\/article\/393af30e4d2694b3\/CRE-59356.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T06:19:26Z","timestamp":1758089966000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dl.begellhouse.com\/journals\/6dbf508d3b17c437,1795a7ae0f352901,393af30e4d2694b3.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1615\/critreveukaryotgeneexpr.2025059356","relation":{},"ISSN":["1045-4403"],"issn-type":[{"value":"1045-4403","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]}}}